Other NMJ Disorders
Beyond autoimmune myasthenia gravis and Lambert–Eaton myasthenic syndrome, a heterogeneous group of disorders can disrupt neuromuscular junction (NMJ) transmission through genetic, toxic, infectious, and pharmacologic mechanisms. These include congenital myasthenic syndromes (CMS), botulism, drug-induced NMJ dysfunction, organophosphate poisoning, tick paralysis, and snake envenomation neurotoxicity. Though individually rare, these conditions share the common endpoint of fatigable or fixed neuromuscular weakness and carry significant morbidity when not recognized promptly. Treatment is highly subtype-specific — some CMS subtypes are worsened by drugs that benefit others, and toxin-mediated conditions each require distinct, time-sensitive interventions.
Bottom Line
- Congenital myasthenic syndromes (CMS): Rare genetic disorders affecting NMJ transmission; ~35 causative genes identified; treatment is subtype-specific and some subtypes (COLQ, DOK7, slow-channel) are worsened by acetylcholinesterase inhibitors
- Botulism: Presynaptic blockade of acetylcholine release causing descending paralysis with bulbar onset, autonomic dysfunction, and fixed dilated pupils; administer antitoxin on clinical suspicion alone — do not wait for laboratory confirmation
- Drug-induced NMJ dysfunction: Aminoglycosides, fluoroquinolones, magnesium, immune checkpoint inhibitors, and D-penicillamine can unmask or exacerbate NMJ disorders; a high index of suspicion is needed in patients with new-onset myasthenic symptoms after drug exposure
- Organophosphate poisoning: Irreversible AChE inhibition causes cholinergic crisis (SLUDGE) followed by nicotinic paralysis; treat with atropine, pralidoxime (before “aging”), and decontamination
- Tick paralysis: Ascending flaccid paralysis mimicking GBS; diagnosis requires thorough skin/scalp examination; complete tick removal produces rapid recovery with Dermacentor species
- Snake envenomation: Elapid venoms cause NMJ blockade via postsynaptic α-neurotoxins (reversible with antivenom) or presynaptic β-neurotoxins (phospholipase A2; irreversible nerve terminal damage); early antivenom is critical
Congenital Myasthenic Syndromes
Congenital myasthenic syndromes (CMS) are a group of rare, genetically determined disorders caused by mutations in genes encoding proteins essential for NMJ structure and function. Approximately 35 genes have been identified to date, and CMS are classified by the location of the affected protein into presynaptic, synaptic, and postsynaptic subtypes. The typical presentation involves fatigable weakness predominantly affecting axial and proximal limb muscles, with variable ocular, bulbar, and respiratory involvement. Onset is usually at birth or in infancy, but later childhood and adult presentations are well recognized — CMS should be considered in all patients with seronegative myasthenia gravis, particularly those with poor response to immunotherapy.
Classification
| Category | Mechanism | Key Genes |
|---|---|---|
| Presynaptic | Defects in ACh synthesis, vesicular transport, or exocytosis | CHAT, SLC5A7, SLC18A3, SNAP25, VAMP1, SYT2, UNC13A, MYO9A |
| Synaptic | Deficiency of synaptic cleft proteins (AChE anchoring, basal lamina) | COLQ, COL13A1, LAMB2, LAMA5 |
| Postsynaptic | AChR deficiency, kinetic abnormalities, or AChR clustering defects | CHRNE, CHRNA, CHRNB, CHRND, RAPSN, DOK7, MUSK, AGRN, LRP4 |
| Glycosylation defects | Impaired AChR assembly due to abnormal protein glycosylation | GFPT1, DPAGT1, ALG2, ALG14, GMPPB |
Common CMS Subtypes
| Gene | Protein / Function | Inheritance | Key Clinical Features | First-Line Treatment |
|---|---|---|---|---|
| CHRNE | AChR ε-subunit (primary AChR deficiency) | AR | Ptosis, ophthalmoparesis (often fixed), facial/bulbar/proximal limb weakness; most common CMS gene | Pyridostigmine; 3,4-DAP or salbutamol as add-on |
| RAPSN | Rapsyn (AChR clustering at endplate) | AR | Neonatal or infantile onset; hypotonia, ptosis, feeding difficulties, recurrent respiratory crises in infancy that subside with age | Pyridostigmine; 3,4-DAP or salbutamol as add-on |
| DOK7 | Downstream of kinase 7 (AChR clustering pathway) | AR | Limb-girdle pattern, ptosis without ophthalmoparesis, progressive respiratory failure; can mimic seronegative MG in adults | Salbutamol (albuterol) or ephedrine; avoid pyridostigmine |
| COLQ | Collagenic tail of AChE (anchors AChE to basal lamina) | AR | Severe neonatal or milder childhood onset; generalized weakness with respiratory involvement; repetitive CMAPs on EMG | Salbutamol or ephedrine; avoid pyridostigmine |
| CHAT | Choline acetyltransferase (ACh synthesis) | AR | Episodic apnea triggered by illness/stress; hypotonia, oculobulbar weakness; cognitive involvement common | Pyridostigmine; 3,4-DAP as add-on |
| Slow-channel CMS | Prolonged AChR channel opening (gain-of-function mutations in AChR subunits) | AD | Childhood to adult onset; selective distal upper limb and neck extensor weakness; progressive course with respiratory failure in 30–50% | Fluoxetine or quinidine; avoid pyridostigmine |
| Fast-channel CMS | Shortened AChR channel opening (loss-of-function mutations in AChR subunits) | AR | Severe neonatal or milder infantile onset; ptosis, ophthalmoplegia, limb and respiratory weakness | Pyridostigmine; 3,4-DAP or salbutamol as add-on |
| Glycosylation (GFPT1, DPAGT1, GMPPB) | Impaired AChR glycosylation and assembly | AR | Childhood to adult onset; limb-girdle pattern with minimal ocular/bulbar involvement; elevated CK; tubular aggregates on biopsy | Pyridostigmine; 3,4-DAP as add-on |
CMS Subtypes Worsened by Acetylcholinesterase Inhibitors
- COLQ CMS: AChE is deficient at the endplate; inhibiting the remaining AChE further prolongs ACh exposure, worsening endplate myopathy and receptor desensitization
- DOK7 CMS: Pyridostigmine and 3,4-DAP can both cause clinical deterioration; treat with beta-2 adrenergic agonists (salbutamol/albuterol or ephedrine) instead
- Slow-channel CMS: The AChR channel is already open too long; AChE inhibitors further prolong ACh action and worsen the depolarization block; use fluoxetine or quinidine as open-channel blockers
- Clinical implication: In patients awaiting genetic confirmation, empirical pyridostigmine must be used with extreme caution and monitored closely for paradoxical worsening
Diagnosis
- Electrodiagnostics: Decremental response (≥10%) on slow (2–3 Hz) repetitive nerve stimulation; some presynaptic CMS subtypes show facilitation with high-frequency stimulation; repetitive CMAPs are characteristic of COLQ and slow-channel CMS; single-fiber EMG shows increased jitter
- Genetic testing: Gene panels or whole-exome sequencing; most subtypes are autosomal recessive, except slow-channel, SNAP25, PURA, and some SYT2 cases (autosomal dominant)
- Key diagnostic clue: Seronegative myasthenia gravis (negative AChR and MuSK antibodies) with onset in infancy/childhood, poor response to immunotherapy, or a family history of fatigable weakness should prompt CMS genetic testing
- Central nervous system involvement: More common in presynaptic CMS subtypes (CHAT, SLC5A7, UNC13A) due to ubiquitous expression of the affected proteins
Treatment Principles
- Acetylcholinesterase inhibitors (pyridostigmine): First-line for most postsynaptic and presynaptic subtypes (CHRNE, RAPSN, CHAT, fast-channel); side effects include nausea, diarrhea, and increased secretions
- 3,4-diaminopyridine (3,4-DAP): Potassium channel blocker that prolongs presynaptic action potential and increases ACh release; used as add-on therapy; side effects include perioral paresthesia and, rarely, seizures at high doses
- Beta-2 adrenergic agonists (salbutamol/albuterol, ephedrine): Stabilize synaptic structure; first-line for DOK7 and COLQ; effects may take months to reach full benefit; monitor ECG, blood pressure, and potassium
- Open-channel blockers (fluoxetine, quinidine): For slow-channel CMS only; quinidine requires cardiac monitoring (QT prolongation risk); fluoxetine carries risk of suicidal ideation
- Emerging therapies: AAV gene replacement therapy for DOK7, COLQ, and CHAT CMS has shown encouraging preclinical results; a phase 1b trial of MuSK agonist antibody for DOK7 CMS is ongoing (NCT06436742)
Botulism
Botulism is a rare, life-threatening disorder caused by botulinum neurotoxin (BoNT), a zinc-dependent endoprotease produced by Clostridium botulinum and related species. BoNT irreversibly cleaves SNARE complex proteins essential for acetylcholine vesicle fusion at the presynaptic terminal, blocking neurotransmitter release. The toxin does not cross the blood-brain barrier, so cognition is preserved throughout. Recovery requires sprouting of new nerve terminals over weeks to months.
Clinical Forms
| Form | Mechanism | Distinguishing Features |
|---|---|---|
| Foodborne | Ingestion of preformed toxin in improperly preserved foods | GI prodrome (nausea, vomiting); median incubation 1 day (range: hours to 12 days); serotype A causes most severe disease |
| Wound | In situ toxin production from wound colonization | No GI prodrome; longer incubation (4–14 days); associated with injection drug use (black-tar heroin) |
| Infant | Intestinal colonization by C. botulinum spores (immature gut flora) | Age 2–8 months (peak); constipation, poor feeding, weak cry, hypotonia; honey exposure in 15–59% |
| Iatrogenic | Systemic spread from cosmetic/therapeutic BoNT injections | Rare with FDA-approved products; reported with counterfeit preparations; onset days to weeks post-injection |
Clinical Presentation
The hallmark is symmetric, descending flaccid paralysis beginning with cranial nerves: diplopia, ptosis, dysarthria, and dysphagia, progressing to limb and respiratory muscle weakness. Fixed, dilated pupils due to parasympathetic cholinergic blockade are a distinguishing feature from myasthenia gravis (where pupils are normal). Autonomic dysfunction includes ileus, urinary retention, dry mouth, and orthostatic hypotension. Deep tendon reflexes are diminished or absent. At presentation, approximately two-thirds of patients have oculobulbar involvement; isolated respiratory failure without cranial nerve palsy is highly unlikely to be botulism.
Botulism Diagnosis
- Clinical diagnosis first: Treatment with antitoxin should be initiated on clinical suspicion alone — laboratory confirmation takes days; serum should be collected before antitoxin administration
- Gold standard: Mouse bioassay (intraperitoneal injection of patient serum into mice; results in 24–96 hours); PCR and mass spectrometry are emerging alternatives
- Specimens: Serum (5–15 mL, without anticoagulant), stool (10–20 g), gastric aspirate, wound culture, and suspected food source
- Electrodiagnostics: Low-amplitude CMAPs; decrement on slow (2 Hz) RNS; facilitation (≥20% increment) on post-exercise or high-frequency (30–50 Hz) stimulation; fibrillation potentials and increased jitter on SFEMG; studies may be normal early in the disease
- Key differentiator from GBS: Descending (not ascending) paralysis; fixed dilated pupils; normal CSF; presynaptic EMG pattern
Treatment
- Heptavalent botulinum antitoxin (BAT): Equine-derived antibodies covering serotypes A–G; neutralizes circulating toxin but does not reverse existing paralysis; most effective within 24–48 hours of symptom onset; available in the US through CDC Emergency Operations
- Infant botulism: Treated with BabyBIG (human-derived anti-A, anti-B botulinum immunoglobulin); reduces hospitalization duration significantly; maximal benefit within 7 days of onset
- Supportive care: ICU monitoring with close attention to respiratory function; 46% of adults require mechanical ventilation (87% within the first 2 days); bulbar dysfunction may independently necessitate intubation
- Prognosis: With appropriate critical care, nearly all patients survive and fully recover; recovery requires new nerve terminal sprouting over weeks to months; neurorehabilitation is essential
Drug-Induced NMJ Dysfunction
Numerous medications can impair NMJ transmission through presynaptic, synaptic, or postsynaptic mechanisms. Drug-induced NMJ dysfunction may present as new-onset myasthenic symptoms in previously healthy individuals, exacerbation of pre-existing MG or CMS, or unmasking of subclinical NMJ disease. Awareness of these agents is critical in perioperative settings, critical care, and routine outpatient management of patients with known NMJ disorders.
Drugs That Impair NMJ Transmission
- Aminoglycosides (gentamicin, tobramycin, neomycin): Block presynaptic calcium channels and reduce ACh release; also have postsynaptic ion channel blocking effects; can precipitate myasthenic crisis in MG patients and cause prolonged post-operative paralysis
- Fluoroquinolones (ciprofloxacin, levofloxacin): Inhibit presynaptic ACh release; FDA black box warning for MG exacerbation; associated with myasthenic crisis even in patients without known NMJ disease
- Magnesium (IV/high-dose): Inhibits presynaptic calcium influx and reduces ACh release; reduces postsynaptic sensitivity; hypermagnesemia can cause clinically significant NMJ blockade, especially in renal insufficiency or pre-eclampsia treatment
- D-Penicillamine: Can induce de novo autoimmune MG with production of AChR antibodies; occurs in 1–7% of patients treated for Wilson disease or rheumatoid arthritis; usually resolves after drug discontinuation, though recovery may take months
- Immune checkpoint inhibitors (nivolumab, pembrolizumab, ipilimumab): Can induce autoimmune MG (often with AChR antibodies), LEMS, or myositis-MG overlap; onset typically within the first 3 months; concurrent myocarditis is a potentially fatal complication; treatment involves drug discontinuation, corticosteroids, and sometimes PLEX/IVIg
- Other antibiotics: Macrolides (azithromycin, telithromycin — especially high-risk), clindamycin, tetracyclines, and polymyxins can impair NMJ transmission to varying degrees
- Other agents: Beta-blockers, calcium channel blockers, procainamide, lithium, phenytoin, botulinum toxin (excessive spread), and neuromuscular blocking agents (prolonged effect in NMJ disease)
| Drug Class | Mechanism at NMJ | Clinical Significance |
|---|---|---|
| Aminoglycosides | Presynaptic Ca2+ channel blockade; postsynaptic ion channel block | Can cause prolonged paralysis post-operatively; avoid in MG |
| Fluoroquinolones | Presynaptic inhibition of ACh release | FDA black box warning; contraindicated in MG |
| Magnesium | Presynaptic Ca2+ blockade; reduced postsynaptic sensitivity | Risk in pre-eclampsia Rx, renal failure; monitor levels closely |
| D-Penicillamine | Induces autoimmune AChR antibody production | True autoimmune MG; usually reversible after drug withdrawal |
| Checkpoint inhibitors | Immune dysregulation → autoimmune MG, LEMS, or myositis | Screen for concurrent myocarditis (troponin); high mortality if untreated |
| Telithromycin | Presynaptic and postsynaptic NMJ blockade | Contraindicated in MG; fatal cases reported |
Organophosphate and Nerve Agent Poisoning
Organophosphates (OPs) — found in pesticides (malathion, parathion, chlorpyrifos) and military nerve agents (sarin, soman, VX, novichok) — irreversibly inhibit acetylcholinesterase by phosphorylating the active-site serine residue. This causes accumulation of acetylcholine at muscarinic and nicotinic receptors throughout the body, producing a characteristic cholinergic crisis followed by neuromuscular paralysis.
Clinical Phases
Cholinergic Crisis: SLUDGE and Nicotinic Effects
- Muscarinic (SLUDGE): Salivation, Lacrimation, Urination, Defecation, GI distress, Emesis; also miosis, bronchospasm, bronchorrhea, and bradycardia
- Nicotinic: Fasciculations, muscle cramping, weakness, paralysis, tachycardia, hypertension (at skeletal muscle and sympathetic ganglia)
- CNS: Agitation, confusion, seizures, coma, central respiratory depression
- Intermediate syndrome (IMS): Develops in 10–40% of cases at 24–96 hours after the cholinergic crisis, even with adequate initial treatment; proximal limb weakness, neck flexor weakness, cranial nerve palsies, and respiratory failure; resolves over 1–3 weeks as new AChE is synthesized
- OPIDN: Organophosphate-induced delayed neuropathy; occurs 2–4 weeks after exposure; distal sensorimotor polyneuropathy due to neuropathy target esterase inhibition; may be permanent
Treatment
| Intervention | Mechanism and Dosing | Key Considerations |
|---|---|---|
| Decontamination | Remove clothing, copious water irrigation of skin | Healthcare workers must use PPE to prevent secondary exposure |
| Atropine | Muscarinic antagonist; 2–4 mg IV, double every 5 min until secretions dry | Endpoint is drying of secretions, not pupil size; large cumulative doses (hundreds of mg) may be needed; does not reverse nicotinic effects |
| Pralidoxime (2-PAM) | AChE reactivator (removes OP from enzyme); 1–2 g IV over 15–30 min, then infusion | Must be given before “aging” of the OP–AChE bond (timing varies by agent: 2 min for soman, 5 hours for sarin, >24 hours for VX); addresses nicotinic symptoms; efficacy in pesticide poisoning is debated |
| Benzodiazepines | Diazepam 5–10 mg IV for seizures | Seizure prophylaxis in severe cases; reduces CNS excitotoxicity |
Tick Paralysis
Tick paralysis is a potentially fatal, fully reversible disorder caused by neurotoxins secreted in the saliva of engorging female ticks. In North America, Dermacentor andersoni (Rocky Mountain wood tick) and D. variabilis (American dog tick) are the most common causative species. In Australia, Ixodes holocyclus is responsible and produces a more severe, prolonged syndrome. The neurotoxin impairs presynaptic acetylcholine release at the NMJ and may also reduce peripheral nerve conduction velocity.
Pathogenesis and Clinical Features
- Onset: Symptoms begin 5–7 days after tick attachment, coinciding with mating-induced rapid engorgement and peak neurotoxin production
- Presentation: Symmetric, ascending flaccid paralysis beginning in the lower extremities, progressing over 24–48 hours; ataxia and gait unsteadiness may precede frank weakness
- Deep tendon reflexes: Diminished or absent (areflexia)
- Bulbar and respiratory involvement: Can occur if the tick is not removed, leading to respiratory failure and death
- Sensory examination: Typically normal (purely motor syndrome)
- Key mimic: Closely resembles Guillain-Barré syndrome clinically, but CSF is normal (no albuminocytologic dissociation) and rapid resolution after tick removal is diagnostic
Diagnosis and Treatment
- Diagnosis: Entirely clinical; no specific laboratory test; EMG may show reduced CMAP amplitudes with normal sensory studies; the critical step is a thorough skin and scalp examination, particularly in children (most commonly affected) — ticks hide in the hairline, behind ears, and in skin folds
- Treatment (North American Dermacentor): Complete tick removal produces rapid resolution, typically within hours; grasp the tick as close to the skin as possible and apply slow, steady reverse traction
- Treatment (Australian Ixodes holocyclus): Symptoms may transiently worsen for 24–48 hours after tick removal due to release of stored toxin; I. holocyclus tick antitoxin should be administered before tick removal; recovery is slower (days to weeks)
- Supportive care: Mechanical ventilation may be needed if respiratory muscles are already compromised at diagnosis
Snake Envenomation Neurotoxicity
Neurotoxic envenomation primarily involves elapid snakes (cobras, kraits, mambas, coral snakes, taipans) and some viperids. Snake venom neurotoxins cause NMJ blockade through two principal mechanisms that differ fundamentally in their reversibility and response to antivenom.
| Toxin Type | Mechanism | Snake Examples | Antivenom Response |
|---|---|---|---|
| α-Neurotoxins (postsynaptic) | Three-finger toxins that competitively antagonize nicotinic AChRs at the motor endplate | Cobras, coral snakes, mambas | Good — antivenom can displace receptor-bound toxin; anticholinesterases (neostigmine + atropine) may provide temporary improvement |
| β-Neurotoxins / Phospholipase A2 (presynaptic) | Enzymatic destruction of presynaptic nerve terminals; depletes ACh vesicles and causes terminal degeneration | Kraits, taipans, tiger snakes, some viperids | Poor once paralysis is established — nerve terminal damage is irreversible; early antivenom prevents progression but does not reverse existing deficit |
Clinical Features
- Progressive ptosis and ophthalmoplegia (often the earliest signs), followed by bulbar weakness (dysphagia, dysarthria), limb paralysis, and respiratory failure
- Respiratory failure may develop within hours of envenomation
- Local signs (pain, swelling, tissue necrosis) may or may not be present depending on the species
- Coagulation abnormalities may coexist, particularly with viperid envenomation
Treatment
- Antivenom: Species-specific antivenom is the definitive treatment; most effective when administered early before toxin binds to targets; particularly critical for presynaptic (β-neurotoxin) envenomation, where nerve terminal damage becomes irreversible
- Anticholinesterase trial: The WHO recommends a trial of neostigmine (0.5 mg IV with atropine 0.6 mg) for elapid envenomation with neuromuscular weakness; more effective for postsynaptic (α-neurotoxin) blockade
- Supportive care: Mechanical ventilation for respiratory failure; may be required for days to weeks with presynaptic envenomation while nerve terminals regenerate
- Emerging therapy: Varespladib, a secretory phospholipase A2 inhibitor, is under investigation as a broad-spectrum adjunct to antivenom for neurotoxic envenomation
References
- Ramdas S, Beeson D, Dong YY. Congenital myasthenic syndromes: increasingly complex. Curr Opin Neurol. 2024;37(5):493–501.
- Ohno K, Ohkawara B, Shen XM, Selcen D, Engel AG. Clinical and pathologic features of congenital myasthenic syndromes caused by 35 genes — a comprehensive review. Int J Mol Sci. 2023;24(3):3730.
- Engel AG, Shen XM, Selcen D, Sine SM. Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment. Lancet Neurol. 2015;14(4):420–434.
- Ramdas S. Botulism, Lambert-Eaton myasthenic syndrome, and congenital myasthenic syndromes. Continuum (Minneap Minn). 2025;31(5):1303–1338.
- Rao AK, Sobel J, Chatham-Stephens K, Luquez C. Clinical guidelines for diagnosis and treatment of botulism, 2021. MMWR Recomm Rep. 2021;70(RR-2):1–30.
- Cosi V, Romani A. Drug-induced myasthenic syndromes. In: Antel JP, Bhatt DK, eds. Handbook of Clinical Neurology. Elsevier; 2024.
- Gilhus NE, Owe JF, Hoff JM, Romi F, Skeie GO, Aarli JA. Drugs that induce or cause deterioration of myasthenia gravis: an update. J Clin Med. 2021;10(7):1537.
- Eddleston M, Buckley NA, Eyer P, Dawson AH. Management of acute organophosphorus pesticide poisoning. Lancet. 2008;371(9612):597–607.
- Grattan-Smith PJ, Morris JG, Johnston HM, et al. Clinical and neurophysiological features of tick paralysis. Brain. 1997;120(Pt 11):1975–1987.
- Mans BJ, Steinmann CM, Hardy NB, et al. Comprehensive analysis of the global impact and distribution of tick paralysis. Clin Microbiol Rev. 2024;37(4):e00074-24.
- Silva A, Isbister GK. Current research into snake antivenoms, their mechanisms of action and applications. Biochem Soc Trans. 2020;48(2):537–546.
- Ranawaka UK, Lalloo DG, de Silva HJ. Neurotoxicity in snakebite — the limits of our knowledge. PLoS Negl Trop Dis. 2013;7(10):e2302.